On May 4, 2020 Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA,OTCQB: MDNAF), a clinical stage immuno-oncology company, reported that it will be presenting two abstracts at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") Virtual Scientific Program to be held from May 29 to May 31, 2020 (Press release, Medicenna Therapeutics, MAY 4, 2020, View Source [SID1234556981]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first abstract has been selected for a poster discussion and will provide new data on tumor response as well as survival outcomes compared to a matched Synthetic Control Arm ("SCA"). Details of the poster discussion presentation are below:

Presenter:

Dr. John Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins
Distinguished Professor and Chair of Neurosurgery, Duke University School of
Medicine

Title:

"MDNA55 survival in recurrent glioblastoma ("rGBM") patients expressing the
interleukin-4 receptor ("IL4R") as compared to a matched synthetic control"

Abstract #:

2513

Session Title:

CNS Tumors

Discussant:

Dr. Ian Parney, MD, PhD

The second abstract will present pre-clinical data including non-human primate data for MDNA11, one of Medicenna’s IL2 Superkine candidates. Details of the poster presentation are below:

Presenter:

Dr. Moutih Rafei, PhD, Associate Professor, Department of Pharmacology and
Physiology, Université de Montreal

Title:

"In vitro and in vivo characteristics of MDNA11: A long-acting ‘Beta-only’
IL-2 Superkine in syngeneic mice tumor models and non-human primates"

Abstract #:

3036

Session Title:

Developmental Therapeutics Immunotherapy

Presentations and posters will be available for on-demand viewing online at View Source beginning on May 29, 2020 at 8:00 a.m. ET.

On May 4, 2020 Protagonist Therapeutics, Inc. (Nasdaq:PTGX) reported that it will announce first quarter financial results after the NASDAQ market closes on Thursday, May 7, 2020 (Press release, Protagonist, MAY 4, 2020, View Source [SID1234556980]). Protagonist management will host a conference call to provide a corporate and R&D update at 5:00 p.m. EDT/2:00 p.m. PDT the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information

Protagonist executives will host a conference call at 5:00 p.m. EDT/2:00 p.m. PDT on Thursday, May 7, 2020. To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and refer to conference ID number 4597494. A live and archived webcast of the call will also be accessible in the Investors section of the Company’s website at www.protagonist-inc.com. A replay will be available on the company’s website approximately two hours after the call and will remain available for 60 days.

On May 4, 2020 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biology solutions provider, owner of Clean Beauty consumer brands and provider of proprietary functional ingredients, reported that the company will host a conference call for investors and analysts on Friday, May 8, 2020 at 6:00 a.m. PT (9:00 a.m. ET) to discuss its first quarter 2020 results (Press release, Amyris Biotechnologies, MAY 4, 2020, View Source [SID1234556979]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release detailing first quarter 2020 results will be issued on the morning of May 8 prior to the call.

On the call, President and Chief Executive Officer John Melo, Chief Financial Officer Han Kieftenbeld, and Chief Operating Officer Eduardo Alvarez will discuss Amyris’ financial results, as well as the company’s business outlook and strategy.

Those who wish to listen to the conference call should dial into (888) 390-3967 (U.S. and International) and ask to be joined to the Amyris, Inc. call. A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: View Source

If you are unable to listen to the live call, the webcast will be archived on the company’s website. A replay of the webcast will be available on the Investor Relations section of the company’s website approximately two hours after the conclusion of the call.

On May 4, 2020 Insmed Incorporated (Nasdaq: INSM) reported that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering (Press release, Insmed, MAY 4, 2020, View Source [SID1234556978]). All of the shares to be sold in the offering are to be sold by Insmed. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Leerink is acting as sole bookrunning manager for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above has been filed with the Securities and Exchange Commission (SEC), as amended by Post-Effective Amendment No. 1 thereto, and became automatically effective upon filing on May 19, 2017. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering may be obtained, when available, from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, by telephone: 1-800-808-7525, ext. 6218 or by email at syndicate@svbleerink.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

On May 4, 2020 NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, reported that management will present at the virtual BofA Securities 2020 Healthcare Conference on Tuesday, May 12 at 5:00 p.m. ET/2:00 p.m. PT (Press release, NuVasive, MAY 4, 2020, View Source [SID1234556977]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the live webcast.